Document Detail

Efficacy and tolerability of cisapride in children.
MedLine Citation:
PMID:  11577921     Owner:  NLM     Status:  MEDLINE    
As gastro-oesophageal reflux disease (GORD) in infants and children is a motility disorder which differs in pathophysiology and clinical course from GORD in adults, prokinetics should be considered the drug of choice in certain circumstances. Indeed, cisapride may result in improvement of feeding tolerance in premature infants. Cisapride has a better tolerability profile than a 'wait-and-see-if-improvement-comes-spontaneously' policy or the other therapeutic options available. A careful and critical review of published data suggests that cisapride may have a QTc-prolonging effect. However, provided the precautions for cisapride administration are followed, the QTc-prolonging effect remains consistently without clinically relevant adverse effects. Correct dosage and avoidance of concurrent treatment with macrolides and/or azoles are the most relevant tolerability recommendations in children. Although there is a need for a prokinetic with better efficacy, cisapride is currently the prokinetic with the best benefit-to-risk ratio available. Thus, withdrawal of cisapride would result in a significantly increased risk for severe complications in infants and children with GORD or other gastrointestinal motility disorders such as chronic intestinal pseudo-obstruction, gastroparesis and feed intolerance in premature infants.
Y Vandenplas; A Benatar; F Cools; A Arana; B Hegar; B Hauser
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Paediatric drugs     Volume:  3     ISSN:  1174-5878     ISO Abbreviation:  Paediatr Drugs     Publication Date:  2001  
Date Detail:
Created Date:  2001-10-01     Completed Date:  2002-01-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100883685     Medline TA:  Paediatr Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  559-73     Citation Subset:  IM    
Academic Children's Hospital, Free University of Brussels,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Child, Preschool
Cisapride* / adverse effects,  therapeutic use
Clinical Trials as Topic / methods
Drug Tolerance
Endpoint Determination
Gastroesophageal Reflux / drug therapy*
Gastrointestinal Agents* / adverse effects,  therapeutic use
Reg. No./Substance:
0/Gastrointestinal Agents; 81098-60-4/Cisapride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early suicide following discharge from a psychiatric hospital.
Next Document:  Recognition and management of scleroderma in children.